🧬
Neurology · October 2025 — IN DEVELOPMENT
Barcelona researchers reverse Alzheimer's in mice with just three nanoparticle injections
In one of the most significant Alzheimer's breakthroughs in years, scientists co-led by the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona reversed Alzheimer's pathology in mice using just three doses of specially designed nanoparticles. Unlike conventional approaches that target neurons, the treatment repairs the blood-brain barrier — restoring the brain's natural ability to clear toxic amyloid-beta proteins.
The nanoparticles, described as"supramolecular drugs", are bioactive in their own right — not merely drug carriers. After just three injections, animal subjects showed measurable cognitive recovery and a striking reduction in Alzheimer's pathology. The study was a collaboration between IBEC, University of Barcelona, University College London, West China Hospital and the Chinese Academy of Medical Sciences, published in Signal Transduction and Targeted Therapy (October 2025).
Lead researcher Dr. Lorena Ruiz Pérez (IBEC / University of Barcelona) stated: the findings show"nanomedicine can go beyond delivery — the nanoparticles themselves can act as active drugs." Human trials have not yet begun. The research team hopes the vascular approach will open a new pathway for clinical intervention.
October 2025 · Dr. Lorena Ruiz Pérez, IBEC / University of Barcelona · Published in Signal Transduction and Targeted Therapy
⚠️ This research is currently limited to animal models. Human clinical trials have not yet begun. No treatment is currently available for patients.
💉
Orthopaedics · 2025 — IN DEVELOPMENT
Injectable gels that teach joints to heal themselves — the cartilage regeneration revolution
Multiple research teams in 2025 have made significant advances in injectable hydrogel therapies that stimulate natural cartilage regeneration — potentially replacing knee and hip replacement surgery for millions of arthritis sufferers worldwide.
A University of Connecticut team, backed by a $2.3M NIH grant, has developed a piezoelectric injectable gel that uses the body's own mechanical movements — such as walking — to generate tiny electrical signals that stimulate cartilage growth. In rabbit studies, the cell-free, drug-free gel produced functional cartilage within two months.
The team's Phase I human trials are planned through 2029. Meanwhile, a Northwestern University biomaterial applied to large animal knee joints showed new cartilage growth within six months (2025). A separate Chinese research team published a dual-drug hydrogel system in Engineering (July 2025) that simultaneously reduces inflammation and promotes cartilage regeneration using natural proteins including collagen and silk.
Current private health cover through Generali includes physiotherapy, orthopaedic specialist consultations and pre-surgical assessments — keeping you optimally managed while this technology develops.
2025 · Multiple research teams · University of Connecticut, Northwestern University, Engineering journal
⚠️ These treatments are in animal studies and early human trial phases. They are not yet available to patients. Standard treatments including physiotherapy and surgery remain the current standard of care.
🦷
Dentistry · 2025 — HUMAN TRIALS UNDERWAY
World's first human trials for a drug that regrows your own teeth — results expected by 2027
Kyoto University Hospital in Japan began the world's first human clinical trials of TRG-035 in September 2024, continuing through 2025 — a drug designed to stimulate growth of a third natural set of teeth in adults. The Phase I safety trial involves 30 male participants aged 30–64 who are missing at least one molar.
The drug targets the USAG-1 protein, which normally suppresses tooth bud development. By blocking USAG-1, dormant third-set tooth buds — which all humans possess but which never normally activate — can be reactivated. In earlier animal studies involving mice, ferrets and dogs, the drug produced new teeth with no significant side effects. The research is being commercialised through Toregem Biopharma, co-founded by lead researcher Dr. Katsu Takahashi of Kitano Hospital, Osaka.
The development timeline: Phase I safety trials through 2025, Phase II efficacy trials in children with congenital tooth loss through 2027, Phase III large-scale trials through 2029. If all phases succeed, the treatment could reach general availability around 2030. It would initially target people with congenital tooth loss, with wider availability for anyone who has lost teeth to decay or injury to follow.
2025 · Dr. Katsu Takahashi, Kyoto University Hospital / Toregem Biopharma, Japan
ℹ️ Human trials are currently underway — but Phase I focuses on safety only. No confirmed results or approved treatments yet. Earliest potential availability: approximately 2030, subject to successful trial completion and regulatory approval.